Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed, operable stage IIIB non-small cell lung cancer
• * T4 N0-3 M0 or T1-4 N3 M0 by bronchoscopy and mediastinoscopy (required for assessment of N3 disease) or CT scan or MRI of the thorax
• * Squamous cell
• * Adenosquamous cell
• * Large cell
• * Poorly differentiated
• No prior or concurrent metastatic disease by CT scan or MRI of the brain, bone scan, and abdominal ultrasound or CT scan
• No malignant pleural or pericardial effusion
• No invasion of the aorta, esophagus, myocardium, or supraclavicular nodes
• PATIENT CHARACTERISTICS:
• Age:
• 18 to 75
• Performance status:
• WHO 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 4,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin normal
• AST and/or ALT no greater than 1.5 times upper limit of normal (ULN)
• Alkaline phosphatase no greater than 2.5 times ULN
• Renal:
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No unstable cardiac disease requiring treatment
• No congestive heart failure
• No angina pectoris (even if medically controlled)
• No significant arrhythmia
• No myocardial infarction within the past 3 months
• Other:
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No definite contraindications for the use of corticosteroids as premedication
• No preexisting grade 2 or greater peripheral neuropathy
• No active uncontrolled infection
• No uncontrolled diabetes mellitus
• No other prior or concurrent malignancy except non-melanomatous skin cancer or adequately treated carcinoma in situ of the cervix
• No prior significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would preclude informed consent
• No other serious underlying medical condition that would preclude study participation
• No socioeconomic or geographical circumstances that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• Not specified
• Endocrine therapy:
• No concurrent corticosteroids except as prophylactic pretreatment medication, treatment for acute hypersensitivity reactions, or chronic treatment (initiated more than 6 months ago) at low-dose (no more than 20 mg methylprednisolone or equivalent)
• Radiotherapy:
• No prior radiotherapy to the chest
• Surgery:
• See Disease Characteristics
• Other:
• At least 30 days since prior treatment in a clinical trial
• No prior cytostatic therapy
• No other concurrent experimental drugs